RxDoctor Payments Data

Richard Fichman, MD

Ophthalmology · Manchester, CTNPI 1134232424

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,800 of the $3,226 with a category attached, or 86.8%. Alcon accounts for 89.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $2,879 and has fallen 96.4% since, to $104 in 2023.

$3,226in general payments, 2019–2025

Across 27 payments — averaging $119.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$3K
  • Kala Pharmaceuticals, Inc.$85
  • Novartis$52
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$50
  • AbbVie$43
  • Bausch & Lomb Americas Inc.$35
  • plus $75 from 4 others

What the payments were for

  • Consulting fees$2,80087%
  • Food & beverage$40813%
  • Education$181%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,226 in reported general payments places this provider in the 80th percentile of 279 ophthalmology providers in Connecticut.

See all ophthalmology providers in Connecticut

Medicare billing

Part B allowed, 2024
$23,577
Medicare patients
36
Services billed
88

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lotemax SmLoteprednol Etabonate41$10,414
BesivanceBesifloxacin Hcl39$8,767
ProlensaBromfenac Sodium19$6,700
Prednisolone Acetate101$6,017
Bromfenac Sodium20$4,194
Ciprofloxacin Hcl101$1,108
Diclofenac Sodium89$1,004
Latanoprost33$432
Ketorolac Tromethamine14$332
Acetazolamide ErAcetazolamide11$34

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Besivance, Prolensa$50$25,88199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 279 ophthalmology providers in Connecticut.

Other ophthalmology in Manchester

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →